Eribulin Accord 0,44 mg/ml otopina za injekciju
| Name | Eribulin Accord 0,44 mg/ml otopina za injekciju |
|---|---|
| Marketing Authorisation Number | HR-H-327971497 |
| Active Substance | eribulinmesilat |
| Composition | jedan ml otopine sadrži 0,44 mg eribulina u obliku eribulinmesilata |
| Pharmaceutical Form | otopina za injekciju |
| Manufacturer | Accord Healthcare Single Member S.A., Lamia, Grčka
Accord Healthcare Polska Sp. z o.o., Pabianice, Poljska |
| Marketing Authorisation Holder | Accord Healthcare Polska Sp. z o.o., Ul. Tasmowa 7, Mazowieckie, Varšava, Poljska |
| Marketing Authorisation Date | 08.06.2026 |
| MA Period of Validity | 08.06.2031 |
| Classification Number | UP/I-530-09/24-01/05 |
| Registration Number | 381-12-01/70-26-11 |
| Prescription | Medicinal product subject to medical prescription |
| Type of prescription | Medicinal product subject to restricted medical prescription |
| Distribution | Supply through pharmacies (community) |
| Advertising to general public | not allowed |
| ATC Code | L01XX41 |
| Marketing status | Never marketed |
| SmPC | download |
| PL | download |
| Public Assessment Report | download |
| Summary of risk management plan | download |